April 1, 2021
By Bio-IT World Staff
April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.
$969M Investment Fund for Early to Late-Stage Companies
Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market. Foresite Capital now has ~$4 billion in assets under management. Press release.
Clocktower Group s Venture Capital Investment Arm Launches Latin America Fintech Fund
crowdfundinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from crowdfundinsider.com Daily Mail and Mail on Sunday newspapers.
Fintech Focus Roundup For March 21, 2021
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Workhorse loses deal and getting sued.
Companies use Clubhouse for earnings.
Dropbox to acquire DocSend for $165M.
TechCrunch talks about memes for sale.
Real Estate: Post-pandemic investment.
Top tech trends to watch closely in 2021.
Market Moving Headline:
Growth versus value worst month since 2000. What does that portend?
For equity bulls, they better hope it’s different this time. In the mid/late 1990s new technologies proliferated and changed the way the world worked. In hindsight, there was a manic period during the last year (1999) that ended poorly for those overly exposed to growth names.
As you can see in the chart below, growth companies have outperformed relative to value for more than a decade. That’s a big cycle. The pandemic work-from-home environment catalyzed a massive move higher in favor of growth. That trend started to reverse in Q4 of last year, with significant capital flows out of growth and into value in February 2021. That cycle warrants attenti